ArticleAllergy, asthma & immunology research2025
Plasma Metabolomic Biomarkers of Middle-Adulthood to Late-Adulthood Atopic Dermatitis: A Prospective Cohort Study From the UK Biobank.
Article in Allergy, asthma & immunology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAlthough atopic dermatitis (AD) in adults has been prevalent, there has been a paucity of previous studies on the metabolic markers linked to its development. We investigated whether plasma metabolomic biomarkers are associated with incident middle-adulthood to late-adulthood AD and identified its predictors.
methodsThis study utilized data collected from the UK Biobank between 2006 and 2010. We prospectively analyzed metabolites in 79,414 participants aged 40 to 69 years, predominantly of European ancestry and free of AD, to assess the incidence of AD, which were collected using the International Classification of Diseases from hospital inpatient admission records from the baseline through 2022. The relationship between these metabolites and the incidence of AD was estimated using Cox proportional hazard models, and the predictive value of the metabolites for the incidence of middle-adulthood to late-adulthood AD was assessed.
resultsThe incidence rate of middle-adulthood to late-adulthood AD was 7.81 per 10,000 person-years, and the median follow-up was 161 months. A total of 35 plasma metabolites included in lipoprotein lipids, fatty acids, amino acids, and biomarkers related to fluid balance were significantly linked to the risk of middle-adulthood to late-adulthood AD incidence. Significant non-linear associations of middle-adulthood to late-adulthood AD incidence were observed with triglycerides in medium very-low density lipoprotein, leucine, and the total concentration of branched-chain amino acids. The incorporation of the identified 35 metabolites with the covariates for middle-adulthood to late-adulthood AD risk prediction achieved an area under the curve of 0.71 (95% confidence interval, 0.67-0.75) and reclassification ability (net reclassification improvement = 21.4%,
conclusionsFindings from this prospective study suggest that the identified plasma metabolites could better clarify the underlying metabolic vulnerabilities and improve risk prediction associated with the development of middle-adulthood to late-adulthood AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.